↓ Skip to main content

Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer

Overview of attention for article published in World Journal of Surgical Oncology, August 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#4 of 2,116)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
18 news outlets
policy
1 policy source
twitter
4 X users
facebook
1 Facebook page

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer
Published in
World Journal of Surgical Oncology, August 2016
DOI 10.1186/s12957-016-0988-0
Pubmed ID
Authors

Pattaraporn Wangchinda, Suthinee Ithimakin

Abstract

Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly aggressive disease in such late-recurring patients. This study investigated predictors of recurrence after more than 5 years in operable breast cancer. We retrospectively analyzed data from patients with recurrent breast cancer treated at Siriraj Hospital. Patients were divided into those whose relapse times were longer or shorter than 5 years. Factors that predicted late recurrence were analyzed in both the overall population and the luminal subgroup. Patterns of relapse, changes in biomarkers, and time to disease progression after first relapse were also recorded. We included 300 women whose breast cancers recurred between 2005 and 2013, of whom 180 had recurrence within 5 years of diagnosis and 120 later than 5 years (median time to recurrence: 45.43 months; range: 4.4-250.3 months). Tumors larger than 2 cm, lymph node metastasis, and high nuclear grade were related with early recurrence. Estrogen receptor-positive, progesterone receptor-positive, and HER2(-) disease predicted late recurrence. Almost all late-relapsing patients with luminal tumors had high estrogen receptor (ER(+)) titers (≥50 %) and HER2(-) disease. Liver and brain were the most common early recurrence sites. Biomarkers did not significantly change by time of recurrence. ER(+)/PR(+) and HER2(-) patients have higher risk of recurrence later than 5 years, especially in patients with high ER titer and low nuclear grade. Larger and node-positive tumors had higher risk of early recurrence.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 94 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 14 15%
Student > Ph. D. Student 13 14%
Other 9 10%
Student > Bachelor 8 9%
Student > Doctoral Student 7 7%
Other 8 9%
Unknown 35 37%
Readers by discipline Count As %
Medicine and Dentistry 27 29%
Biochemistry, Genetics and Molecular Biology 9 10%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Neuroscience 3 3%
Engineering 3 3%
Other 9 10%
Unknown 37 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 150. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 October 2023.
All research outputs
#260,674
of 24,570,543 outputs
Outputs from World Journal of Surgical Oncology
#4
of 2,116 outputs
Outputs of similar age
#5,284
of 348,265 outputs
Outputs of similar age from World Journal of Surgical Oncology
#1
of 27 outputs
Altmetric has tracked 24,570,543 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,116 research outputs from this source. They receive a mean Attention Score of 2.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,265 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.